Arabic Arabic English English French French German German
dark

Pfizer acquires Amplyx Pharmaceuticals

PfizerPfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Carb-X awards up to $3m to GenomeKey for rapid sepsis diagnostic

Next Post

Over a quarter of UK adults have received both COVID-19 vaccine doses

Related Posts
Total
0
Share